Lisa Astor
Articles
Niraparib, Abiraterone, and Prednisone Triplet Shows Efficacy, Safety in mCRPC With HRR Gene Alterations
May 19, 2022
Article
The combination of PARP inhibition and androgen receptor targeted therapy was found to be tolerable in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations.
Frontline Belzutifan Associated with Meaningful Clinical Activity in Treatment of VHL-Associated RCC
July 09, 2021
Article
A phase 2 study reported clinical efficacy from the use of frontline belzutifan in patients with Von-Hippel Lindau (VHL).
Lifileucel Proves Efficacy in Pretreated Advanced Melanoma
April 12, 2021
Article
Lifileucel produced durable responses in advanced melanoma that was previously treated an an immunotherapy agent.
Study Highlights Racial Disparities in Blood Cancer Diagnoses, Outcomes
June 22, 2020
Article
Significant differences were seen between Hispanic and non-Hispanic white patients with hematological malignancies in Texas in terms of the age of diagnosis and long-term survival outcomes. A population study presented in a press program ahead of the 2020 AACR Virtual Annual Meeting II revealed the health disparities between these 2 populations, including for patients living near the US/Mexico border.
Recent Chemotherapy May Increase COVID-19 Mortality Risk for Patients With Thoracic Cancer
May 29, 2020
Article
Chemotherapy administered within 3 months of a diagnosis of coronavirus disease 2019 (COVID-19) increased the risk of death in patients with thoracic cancer, according to findings from the global TERAVOLT Consortium registry.
For Patients with KRAS G12C-mutated NSCLC a New Inhibitor Was Granted a Fast Track Designation
September 10, 2019
Article
The FDA has granted a fast track designation to the KRAS inhibitor AMG 510 for the treatment of patients who received prior treatment with KRAS G12C-mutated NSCLC.
Precision Medicine Is Possible for Pediatric Patients
May 19, 2019
Article
According to the MATCH trial, about a quarter of pediatric patients with cancer were able to be screened for targetable alterations in their tumor and directed to a treatment targeting that alteration.
EGFR-Targeted Activity Helps Differentiation Between TKIs in NSCLC
February 02, 2019
Article
In a presentation during the 16th Annual Winter Lung Conference™, Gregory J. Riely, MD, PhD, discussed the spectrum of activity of many of these FDA-approved EGFR TKIs.
Pivotal Phase III Trial Initiated to Investigate Role of Cabozantinib in Advanced HCC
December 29, 2018
Article
A large pivotal phase III trial has been initiated to evaluate the potential for the first-line combination of cabozantinib (Cabometyx) and atezolizumab (Tecentriq) in comparison with standard-of-care sorafenib (Nexavar) for patients with advanced hepatocellular carcinoma (HCC).
Earlier Adjuvant Chemotherapy Benefits Patients With TNBC
December 14, 2018
Article
Delayed treatment with chemotherapy of more than 30 days after surgery for patients with triple-negative breast cancer (TNBC) is associated with worse survival rates and outcomes than those who receive adjuvant chemotherapy within 30 days of their procedure, according to findings from a retrospective study performed in Peru presented at the 2018 San Antonio Breast Cancer Symposium (SABCS).